Literature DB >> 33502600

Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.

Claudia Stanciu-Pop1, Marie-Cécile Nollevaux1, Martine Berlière2,3, Francois P Duhoux2,3,4, Latifa Fellah3,5, Christine Galant2,3,6, Mieke R Van Bockstal7,8,9.   

Abstract

Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous disease in terms of morphological characteristics, protein expression profiles, genetic abnormalities, and potential for progression. Molecular heterogeneity has been extensively studied in DCIS. Yet morphological heterogeneity remains relatively undefined. This study investigated morphological intratumor heterogeneity in a series of 51 large DCIS. Nuclear atypia, DCIS architecture, necrosis, calcifications, stromal architecture, and stromal inflammation were assessed in one biopsy slide and three representative slides from each corresponding resection. For each histopathological feature, a histo-score was determined per slide and compared between the biopsy and the resection, as well as within a single resection. Statistical analysis comprised of Friedman tests, post hoc Wilcoxon tests with Bonferroni corrections, Mann-Whitney U tests, and chi-square tests. Despite substantial morphological heterogeneity in around 50% of DCIS, the histopathological assessment of the biopsy did not statistically significantly differ from the resection. Morphological heterogeneity was not significantly associated with patient age, DCIS size, or type of surgery, except for a weak association between heterogeneous stromal inflammation and smaller DCIS size. At the group level, the degree of heterogeneity did not significantly affect the representativity of a biopsy. At the individual patient level, however, the presence of necrosis, intraductal calcifications, myxoid stromal changes, and high-grade nuclear atypia was underestimated in a minority of DCIS patients. This study confirms the presence of morphological heterogeneity in DCIS for all six evaluated histopathological features. This should be kept in mind when taking biopsy-based treatment decisions for DCIS patients.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Breast; Ductal carcinoma in situ; Histopathology; Intratumor heterogeneity; Tumor-infiltrating lymphocytes

Mesh:

Year:  2021        PMID: 33502600     DOI: 10.1007/s00428-021-03040-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  39 in total

Review 1.  Prognostic role of immune infiltrates in breast ductal carcinoma in situ.

Authors:  Xiao-Yang Chen; Joe Yeong; Aye Aye Thike; Boon Huat Bay; Puay Hoon Tan
Journal:  Breast Cancer Res Treat       Date:  2019-05-27       Impact factor: 4.872

2.  Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.

Authors:  Susan C Lester; Shikha Bose; Yunn-Yi Chen; James L Connolly; Monica E de Baca; Patrick L Fitzgibbons; Daniel F Hayes; Celina Kleer; Frances P O'Malley; David L Page; Barbara L Smith; Donald L Weaver; Eric Winer
Journal:  Arch Pathol Lab Med       Date:  2009-01       Impact factor: 5.534

3.  Cytological and architectural heterogeneity in ductal carcinoma in situ of the breast.

Authors:  C M Quinn; J L Ostrowski
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

4.  Cancer statistics: Breast cancer in situ.

Authors:  Elizabeth M Ward; Carol E DeSantis; Chun Chieh Lin; Joan L Kramer; Ahmedin Jemal; Betsy Kohler; Otis W Brawley; Ted Gansler
Journal:  CA Cancer J Clin       Date:  2015-10-02       Impact factor: 508.702

5.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation.

Authors:  Beryl McCormick; Kathryn Winter; Clifford Hudis; Henry Mark Kuerer; Eileen Rakovitch; Barbara L Smith; Nour Sneige; Jennifer Moughan; Amit Shah; Isabelle Germain; Alan C Hartford; Afshin Rashtian; Eleanor M Walker; Albert Yuen; Eric A Strom; Jeannette L Wilcox; Laura A Vallow; William Small; Anthony T Pu; Kevin Kerlin; Julia White
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

6.  A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial.

Authors:  S E Pinder; C Duggan; I O Ellis; J Cuzick; J F Forbes; H Bishop; I S Fentiman; W D George
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

7.  Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions.

Authors:  W J Lennington; R A Jensen; L W Dalton; D L Page
Journal:  Cancer       Date:  1994-01-01       Impact factor: 6.860

8.  Comparison of cytomorphological and architectural heterogeneity in mammographically-detected ductal carcinoma in situ.

Authors:  M Harrison; J D Coyne; T Gorey; P A Dervan
Journal:  Histopathology       Date:  1996-05       Impact factor: 5.087

Review 9.  Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions.

Authors:  Stacey K Mardekian; Alessandro Bombonati; Juan P Palazzo
Journal:  Hum Pathol       Date:  2015-11-17       Impact factor: 3.466

Review 10.  A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.

Authors:  Mieke R Van Bockstal; Marie C Agahozo; Linetta B Koppert; Carolien H M van Deurzen
Journal:  Int J Cancer       Date:  2019-05-08       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.